Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
This study has been completed.
Study NCT01027013   Information provided by Acucela Inc.

First Received on December 4, 2009.   Last Updated on January 9, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Dry Eye Syndromes
Keratoconjunctivitis Sicca
Additional conditions recognized in this trial
Keratoconjunctivitis
More general conditions related to this trial
Conjunctival Diseases
Conjunctivitis
Corneal Diseases
Eye Diseases
Keratitis
Lacrimal Apparatus Diseases
Interventions listed in this trial
rebamipide 2% ophthalmic suspension
placebo eye drops
Additional drug interventions recognized in this trial
Rebamipide
Tetrahydrozoline
More general drug interventions related to this trial
Anti-Ulcer Agents
Antioxidants
Autonomic Agents
Cardiovascular Agents
Enzyme Inhibitors
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Nasal Decongestants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Respiratory System Agents
Sympathomimetics
Therapeutic Uses
Vasoconstrictor Agents
Sponsors listed in this trial
Acucela Inc.
Otsuka Pharmaceutical Co., Ltd.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services